Valsartan

References

• Dzau VJ, Bernstein K, Celermajer D, Cohen J, et al. for the Working Group on Tissue Angiotensin-converting enzyme, International Society of Cardiovascular Pharmacotherapy. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88:1L–20L
   Google Scholar
• Ardaillou R. Active fragments of angiotensin II: enzymatic pathways of synthesis and biological effects. Curr Opin Nephrol Hypertens 1997; 6:28–34
   PubMed Web of Science ®Google Scholar
• Vauquelin G, Michotte Y, Smolders I, Sarre S, et al. Cellular targets for angiotensin II fragments: pharmacological and molecular evidence. J Renin Angiotensin Aldosterone Syst 2002;3:195–204
   PubMed Web of Science ®Google Scholar
• Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 2001;12:157–62
   PubMed Web of Science ®Google Scholar
• Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest 1995;96:2515–20
   Google Scholar
• Wright JW, Harding JW. Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res Brain Res Rev 1997;25:96–124
   PubMedGoogle Scholar
• Donoghue M, Hsieh F, Baronas E, Godbout K, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:E1–E9
   PubMed Web of Science ®Google Scholar
• Tipnis SR, Hooper NM, Hyde R, Karran E, et al. A human homolog of angiotensin-converting enzyme - Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000;275:33238–43
   PubMed Web of Science ®Google Scholar
• Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 2003;13:93–101
   PubMed Web of Science ®Google Scholar
• Husain A, Li M, Graham RM. Do studies with ACE Nand C-domain-selective inhibitors provide evidence for a non-ACE, non-chymase angiotensin II-forming pathway? Circ Res 2003; 93:91–3
   PubMed Web of Science ®Google Scholar
• Kokkonen JO, Lindstedt KA, Kovanen PT. Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms? Circulation 2003;107:2555–8
   PubMed Web of Science ®Google Scholar
• Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, et al. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res 2002;91:1038–45
   PubMed Web of Science ®Google Scholar
• English V, Cassis L. Facilitation of sympathetic neuro-transmission contributes to angiotensin regulation of body weight. J Neural Transm 1999;106:631–44
   PubMed Web of Science ®Google Scholar
• Wolf G, Wenzel U, Hannken T, Stahl RA. Angiotensin II induces p27(Kip1) expression in renal tubules in vivo: role of reactive oxygen species. J Mol Med 2001; 79(7): 382–9.
   PubMed Web of Science ®Google Scholar
• Sadoshima J. Cytokine actions of angiotensin II. Circ Res 2000;86:1187–9
   PubMed Web of Science ®Google Scholar
• Seshiah PN, Weber DS, Rocic P, Valppu L, et al. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002;91:406–13
   PubMed Web of Science ®Google Scholar
• Touyz RM, Chen X, Tabet F, Yao G, et al. Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries: regulation by angiotensin II. Circ Res 2002;90:1205–13
   PubMed Web of Science ®Google Scholar
• Matsubara H, Inada M. Molecular insights into angiotensin II type 1 and type 2 receptors: expression, signaling and physiological function and clinical application of its antagonists. Endocr J 1998;45:137–50
   PubMed Web of Science ®Google Scholar
• Cao Z, Kelly DJ, Cox A, Casley D, et al. Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 2000; 8:2437–51
   Google Scholar
• Stoll M, Meffert S, Stroth U, Unger T. Growth or antigrowth: angiotensin and the endothelium. J Hypertens 1995;13:1529–34
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999;104:925–35
   PubMed Web of Science ®Google Scholar
• Gross V, Schunck WH, Honeck H, Milia AF, et al. Inhibition of pressure natriuresis in mice lacking the AT2 receptor. Kidney Int 2000;57:191–202
   PubMed Web of Science ®Google Scholar
• Siragy HM, Carey RM. The subtype 2 angiotensin receptor regulates renal prostaglandin F2 alpha formation in conscious rats. Am J Physiol 1997;273:R1103–7
   Google Scholar
• Garcia-Villalba P, Denkers ND, Wittwer CT, Hoff C, et al. Real-time PCR quantification of AT1 and AT2 angiotensin receptor mRNA expression in the developing rat kidney. Nephron Exp Nephrol 2003;94:e154–9
   Google Scholar
• Ruiz-Ortega M, Esteban V, Suzuki Y, Ruperez M, et al. Renal expression of angiotensin type 2 (AT2) receptors during kidney damage. Kidney Int Suppl 2003; 86:S21–6
   Google Scholar
• Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2(AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999;96:6506–10
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Maeschima Y, Satoh M, Odawara M, et al. Overexpression of angiotensin type 2 receptor ameliorates glomerular injury in a mouse remnant kidney model. Am J Physiol Renal Physiol 2004;286:F516–25
   Web of Science ®Google Scholar
• Iwai N, Inagami T. Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett 1992;298:257–60
   PubMed Web of Science ®Google Scholar
• Kitami Y, Okura T, Marumoto K, Wakamiya R, et al. Differential gene expression and regulation of type-1 angiotensin II receptor subtypes in the rat. Biochem Biophys Res Commun 1992;188:446–52
   PubMed Web of Science ®Google Scholar
• Tian Y, Baukal AJ, Sandberg K, Bernstein KE, et al. Properties of AT1a and AT1b Angiotensin receptors expressed in adrenocortical Y-1 cells. Am J Physiol Endocrinol Metab 1996;270:E831–9
   Web of Science ®Google Scholar
• Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 1988;77:I4–13
   PubMed Web of Science ®Google Scholar
• Garcia VM, Monasterolo LA, Elias MM. Renal vascular responsiveness to angiotensin II at an early stage of diabetes: interaction between intrarenal noradrenergic and renin-angiotensin systems. Acta Diabetol 2003;40:130–6
   PubMed Web of Science ®Google Scholar
• Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000;86:494–501
   PubMed Web of Science ®Google Scholar
• Lopez B, Salom MG, Arregui B, Valero F, et al. Role of superoxide in modulating the renal effects of angiotensin II. Hypertension 2003;42:1150–6
   PubMed Web of Science ®Google Scholar
• Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343–6
   PubMed Web of Science ®Google Scholar
• Niu T, Chen X, Xu X. Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications. Drugs 2002;62:977–93
   PubMed Web of Science ®Google Scholar
• Baudin B. Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations. Pharmacogenomics 2002;3:65–73
   Google Scholar
• Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 1994;23:258–68
   PubMed Web of Science ®Google Scholar
• Zhuo JL, Froomes P, Casley D, Liu JJ, et al. Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation 1997;96:174–82
   PubMed Web of Science ®Google Scholar
• Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 199l;68:450–6
   Google Scholar
• Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for infiammation and plaque instability. Circulation 2000;101:1372–8
   PubMed Web of Science ®Google Scholar
• Chen H, Li D, Mehta JL. Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-kappa B by losartan in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 2002;39:332–9
   PubMed Web of Science ®Google Scholar
• Rabbani R, Topol EJ. Strategies to achieve coronary arterial plaque stabilization. Cardiovasc Res 1999;41:402–17
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pepine CJ, Garces C, Pouleur H, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173–8
   PubMed Web of Science ®Google Scholar
• Rutherford JD, Pfeffer MA, Moye LA, Davis BR, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994;90:1731–8
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Keane WF, et al. and the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9
   Google Scholar
• Pieruzzi F, Abassi ZA. Keiser HR. Expression of reninangiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure. Circulation 1995;92:3105–12
   Google Scholar
• Ruzicka M, Skarda V, Leenen FH. Effects of ACE inhibitors on circulating versus cardiac angiotensin II in volume overload-induced cardiac hypertrophy in rats. Circulation 1995;92:3568–73
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Talsness CE, Schunkert H, Paul M, et al. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991;69:475–82
   PubMed Web of Science ®Google Scholar
• Hokimoto H, Yasue K, Fujimoto H, Yamamoto K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 1996;94:1513–8
   PubMed Web of Science ®Google Scholar
• Kakishita M, Nakamura K, Asanuma M, Morita H, et al. Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type 1a receptor. J Cardiovasc Pharmacol 2003;42:S67–70
   Web of Science ®Google Scholar
• Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hyper-trophy of cardiac myocytes in vitro. Cell 1993,95:977–84
   Google Scholar
• Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 1994;23:869–77
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, Basta L, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669–77
   Google Scholar
• Pitt B, Zannad F, Remme WJ, Cody R, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341(10): 709–17
   PubMed Web of Science ®Google Scholar
• Navar LG, Inscho EW, Majid SA, Imig JD, et al. Paracrine regulation of the renal microcirculation. Physiol Rev 1996;76:425–536
   PubMed Web of Science ®Google Scholar
• Johnston CI, Fabris B, Jandeleit K. Intrarenal reninangiotensin system in renal physiology and pathophysiology. Kidney Int Suppl 1993;42:S59–63
   Google Scholar
• Ploth DW. Angiotensin-dependent renal mechanisms in two-kidney, one-clip renal vascular hypertension. Am J Physiol 1983;245:F131–41
   PubMed Web of Science ®Google Scholar
• Stockand JD, Sansom SC. Glomerular mesangial cells: electrophysiology and regulation of contraction. Physiol Rev 1998;78:723–44
   PubMed Web of Science ®Google Scholar
• Neuringer JR, Brenner BM. Glomerular hypertension: cause and consequence of renal injury. J Hypertens Suppl 1992;10:S91–7
   Google Scholar
• Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002;39:129–34
   PubMed Web of Science ®Google Scholar
• Morris BJ, Johnston CI. Isolation of renin granules from rat kidney cortex and evidence for an inactive form of renin(prorenin) in granules and plasma. Endocrinology 1976;98:1466–74
   PubMed Web of Science ®Google Scholar
• Navar LG, Harrison-Bernard LM, Imig JD, Wang CT, et al. Intrarenal angiotensin II generation and renal effects of AT1 receptor blockade. J Am Soc Nephrol 1999;10:S266- 72
   Google Scholar
• Zatz R, Dunn BR, Meyer TW, Brenner B. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925–30
   PubMed Web of Science ®Google Scholar
• Anderson S, Rennke HG, Garcia DL, Brenner BM. Short and long term effects of antihypertensive therapy in the diabetic rat. Kidney Inter 1989;36:526–36
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998;41:47–53
   PubMed Web of Science ®Google Scholar
• Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990;344:541–4
   PubMed Web of Science ®Google Scholar
• Kelly DJ, Wilkinson-Berka JL, Cooper ATJ, Skinner SL. A new model of progressive diabetic renal impairment in the transgenic (mRen-2)27 rat. Kidney Int 1998;54:343–52
   Google Scholar
• Huang W, Gallois Y, Bouby N, Bruneval P, et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci USA 2001;98:13330–4
   PubMed Web of Science ®Google Scholar
• Price DA, Porter LE, Gordon M, Fisher ND, et al. The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 1999;10:2382–91
   PubMed Web of Science ®Google Scholar
• Anderson S, Jung FF, Ingelfinger JR. Renal reninangiotensin system in diabetes: functional, immunohisto-chemical, and molecular biological correlations. Am J Physiol 1993;265:F477–86
   Google Scholar
• Zimpelmann J, Kumar D, Levine DZ, Wehbi G, et al. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 2000;58:2320–30
   PubMed Web of Science ®Google Scholar
• Choi KC, Kim NH, An MR, Kang DG, et al. Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats. Kidney Int Suppl 1997;60:S23–7
   Google Scholar
• Brown L, Wall D, Marchant C, Sernia C. Tissue-specific changes in angiotensin II receptors in streptozotocin-diabetic rats. J Endocrinol 1997;154:355–62
   PubMed Web of Science ®Google Scholar
• Wehbi GJ, Zimpelmann J, Carey RM, Levine DZ, et al. Early streptozotocin-diabetes mellitus downregulates rat kidney AT2 receptors. Am J Physiol Renal Physiol 2001;80:F254–65
   Google Scholar
• Vallon V, Huang DY, Deng A, Richter K, et al. Salt-sensitivity of proximal reabsorption alters macula densa salt and explains the paradoxical effect of dietary salt on glomerular filtration rate in diabetes mellitus. J Am Soc Nephrol 2002;13:1865–71
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, et al. Increased bradykinin and ''normal'' angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. Kidney Int 1999;56:211–21
   PubMed Web of Science ®Google Scholar
• Anderson S. Physiologic actions and molecular expression of the renin-angiotensin system in the diabetic rat. Miner Electrolyte Metab 1998;24:406–11
   PubMedGoogle Scholar
• Mizuiri S, Yoshikawa H, Tanegashima M, Miyagi M, et al. Renal ACE immunohistochemical localization in NIDDM patients with nephropathy. Am J Kidney Dis 1998;31:301–7
   PubMed Web of Science ®Google Scholar
• Danser AH. Local renin-angiotensin systems: the unanswered questions. Int J Biochem Cell Biol 2003;35:759–68
   PubMed Web of Science ®Google Scholar
• Leung PS. Pancreatic renin-angiotensin system: a novel target for the potential treatment of pancreatic diseases? J Pancreas 2003;4:89–91
   PubMedGoogle Scholar
• Carlsson PO. The renin-angiotensin system in the endocrine pancreas. J Pancreas 2001;2:26–32
   PubMedGoogle Scholar
• Tahmasebi M, Puddefoot JR, Inwang ER, Vinson GP. The tissue renin-angiotensin system in human pancreas. J Endocrinol 1999;161:317–22
   PubMed Web of Science ®Google Scholar
• Carlsson PO, Berne C, Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998;41:127–33
   PubMed Web of Science ®Google Scholar
• Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, et al. Improved islet morphology after blockade of the renin angiotensin system in the zucker diabetic fatty rat. Diabetes 2004 Apr;53(4):989–97
   PubMed Web of Science ®Google Scholar
• Johnston CI, Burrell LM. Evolution of blockade of the renin-angiotensin system. J Hum Hypertens 1995;9:375–80
   Google Scholar
• Stanton A. Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 2003;3:389–94
   PubMedGoogle Scholar
• Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 1977;196:441–4
   PubMed Web of Science ®Google Scholar
• Johnston CI. Angiotensin II type 1 receptor blockade: a novel therapeutic concept. Blood Press Suppl 2000;1:9-13
   Google Scholar
• Skidgel RA, Erdos EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exp Hypertens A 1987;9:243–59
   PubMed Web of Science ®Google Scholar
• Linz L, Wiemer G, Gohlke P, Unger T, et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25–49
   PubMed Web of Science ®Google Scholar
• Gainer JV, Morrow JD, Loveland A, King DJ, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285–92
   Google Scholar
• Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992;117:234–42
   PubMed Web of Science ®Google Scholar
• Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003;5:408–17
   PubMed Web of Science ®Google Scholar
• Brewster UC, Setaro JF, Perazella MA. The reninangiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 2003;326:15–24
   PubMed Web of Science ®Google Scholar
• van Hooft IM, Grobbee DE, Derkx FH, de Leeuw PW, et al. Renal hemodynamics and the renin-angiotensinaldosterone system in normotensive subjects with hyper-tensive and normotensive parents. N Engl J Med 1991;324:1305–11
   PubMed Web of Science ®Google Scholar
• Johnston CI, Naitoh M, Burrell LM. Rationale and pharmacology of angiotensin II receptor antagonists: Current status and future issues. J Hypertens 1997;15(Suppl):S3–6
   Google Scholar
• Johnson T. A comparison of selective Angiotensin II1 receptor antagonists. Curr Ther 1999;40:45–51
   Google Scholar
• Criscione L, de Gasparo M, Buhlmayer P, Whitebread S, et al. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of theangiotensin II AT1-receptor subtype. Br J Pharmacol 1993;110:761–71
   PubMed Web of Science ®Google Scholar
• Colussi DM, Parisot C, Rossolino ML, Brunner LA, et al. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J Clin Pharmacol 1997; 37:214–21. www.pharma.us.novartis.com/product/pi/pdf/Diovan.pdf
   Google Scholar
• Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an Angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol 1997;52:115–20
   PubMed Web of Science ®Google Scholar
• Waldmeier F, Flesch G, Muller P, Winkler T, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997;27:59–71
   PubMed Web of Science ®Google Scholar
• Sechaud R, Graf P, Bigler H, Gruendl E, et al. Bioequivalence study of a valsartan tablet and a capsule formulation after single dosing in healthy volunteers using a replicated crossover design. Int J Clin Pharmacol Ther 2002;40:35–40
   PubMedGoogle Scholar
• Muller P, Flesch G, de Gasparo M, Gasparini M, et al. Pharmacokinetics and pharmacodynamic effects of the Angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects. Eur J Clin Pharmacol 1997;52:441–9
   PubMed Web of Science ®Google Scholar
• Sifton DW, ed. Physicians Desk Reference. Montvale, NJ: Medical Economics Company Inc, 2000:2015–7
   Google Scholar
• Kalbag j, Prasad P, Redalieu E. Plasma concentrations and antihypertensive effects of 10 to 160 mg doses of valsartan in hypertensive patients. Pharm Res 1994;11:S367
   Google Scholar
• Daneshtalab N, Lewanczuk RZ, Russell A, Jamali F. Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan. J Clin Pharmacol 2004;44:245–52
   PubMed Web of Science ®Google Scholar
• Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five Angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000;56:135–40
   PubMed Web of Science ®Google Scholar
• Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. Drug Safety 2003;26:707–2
   PubMed Web of Science ®Google Scholar
• Sioufi A, Marfil F, Jaouen A, Cardot JM, et al. The effect of age on the pharmacokinetics of valsartan. Biopharm Drug Dispos 1998;19:237–44
   PubMed Web of Science ®Google Scholar
• Majahalme S. Demographics, treatment regimens and the use of angiotensin-receptor blockers in heart failure: findings from the Valsartan Heart Failure Trial. J Int Med Res 2003;31:351–61
   PubMedGoogle Scholar
• Prasad PP, Yeh CM, Gurrieri P, Glazer R, et al. Pharmacokinetics of multiple doses of valsartan in patients with heart failure. J Cardiovasc Pharmacol 2002;40:801–7
   PubMed Web of Science ®Google Scholar
• Morgan JM, Palmisano M, Piraino A, Hirschhorn W, et al. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects. Clin Pharmacol Ther 1997;61:35–44
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, et al. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18:89–95
   Google Scholar
• Leidig MF, Delles C, Kuchenbecker C, Lederle RAM, et al. Pharmacokinetics of valsartan in hypertensive patients on longterm haemodialysis. Clin Drug Invest 2001;21:59–66
   Google Scholar
• Brookman LJ, Rolan PE, Benjamin IS, Palmer KR, et al. Pharmacokinetics of valsartan in patients with liver disease. Clin Pharmacol Ther 1997;62:272–8
   PubMed Web of Science ®Google Scholar
• Bindschedler M, Degen P, Flesch G, de Gasparo M, et al. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 1997;52:371–8
   PubMed Web of Science ®Google Scholar
• Edwards RM, Stack EJ, Trizna W. Transport of [3H] losartan across isolated perfused rabbit proximal tubule. J Pharmacol Exp Ther 1999;290:38–42
   PubMedGoogle Scholar
• Schmidt EK, Antonin KH, Flesch G, Racine-Poon A. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol 1998;53:451–8
   PubMed Web of Science ®Google Scholar
• Leung M, Remick RA. Potential drug interaction between lithium and valsartan. J Clin Psychopharmacol 2000;20:392–3
   PubMed Web of Science ®Google Scholar
• de Gasparo M, Whitebread S. Binding of valsartan to mammalian Angiotensin AT1 receptors. Regul Pept 1995;59:303–11
   PubMed Web of Science ®Google Scholar
• Verheijen I, Fierens FL, Debacker JP, Vauquelin G, et al. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors. Fundam Clin Pharmacol 2000;14:577–85
   PubMed Web of Science ®Google Scholar
• Timmermans PB. Pharmacological properties of Angiotensin II receptor antagonists. Can J Cardiol 1999;15(Suppl):26–8F
   Google Scholar
• Latif F, Tandon S, Obeleniene R, Hankins SR, et al. Angiotensin II type 1 receptor blockade with 80 and 160 mg valsartan in healthy, normotensive subjects. J Card Fail 2001;7:265–8
   PubMed Web of Science ®Google Scholar
• Csajka C, Buclin T, Brunner HR, Biollaz J. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997;32:1–29
   PubMed Web of Science ®Google Scholar
• Sironi L, Calvio AM, Arnaboldi L, Corsini A, et al. Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells. Hypertension 2001;37:961–6
   PubMed Web of Science ®Google Scholar
• Muller P, Cohen T, de Gasparo M, Sioufi A, et al. Angiotensin II receptor blockade with single doses of Valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994;47:231–45
   PubMed Web of Science ®Google Scholar
• Lottermoser K, Unger T, Gohlke P, Vetter H, et al. Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans. Am J Hypertens 2003;16:445–52
   PubMedGoogle Scholar
• Ohbayashi Y, Tsutamoto T, Sakaguchi T, Tanaka T, et al. Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol 2003;42(Suppl): S71–4
   PubMedGoogle Scholar
• Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999;99:2658–64
   PubMed Web of Science ®Google Scholar
• Siragy HM, de Gasparo M, El-Kersh M, Carey RM. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001;38:183–6
   PubMed Web of Science ®Google Scholar
• Liu YH, Yang XP, Mehta D, Bulagannawar M, et al. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen-deficient rats. Am J Physiol Heart Circ Physiol 2000;278:H507–14
   Google Scholar
• Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000;35:1074–7
   PubMed Web of Science ®Google Scholar
• Wu L, Iwai M, Nakagami H, Li Z, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of infiammation-induced vascular injury. Circulation 2001;104:2716–21
   PubMed Web of Science ®Google Scholar
• Jugdutt BI, Menon V. Valsartan-induced cardioprotection involves angiotensin II type 2 receptor upregulation in dog and rat models of in vivo reperfused myocardial infarction. J Card Fail 2004;10:74–82
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Hayashi N, Kometani M, Nakao K, et al. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models. Arzneimittelforschung 1997;47:604–12
   PubMedGoogle Scholar
• Wood JM, Schnell CR, Levens NR. Kidney is an important target for the antihypertensive action of an angiotensin II receptor antagonist in spontaneously hypertensive rats. Hypertension 1993;21:1056–61
   PubMed Web of Science ®Google Scholar
• Madrid MI, Garcia-Salom M, Tornel J, De Gasparo M, et al. Effect of interactions between nitric oxide and angiotensin II on pressure diuresis and natriuresis. Am J Physiol 1997;273:R1676–82
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR Jr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997;55:244–51
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Lippert TH. Valsartan inhibits angiotensin II-stimulated proliferation of smooth muscle cells from human coronary artery. Int J Clin Pharmacol Ther 1999;37:365–6
   PubMed Web of Science ®Google Scholar
• Oubina MP, de Las Heras N, Vazquez-Perez S, Cediel E, et al. Valsartan improves fibrinolytic balance in athero-sclerotic rabbits. J Hypertens 2002;20:303–10
   PubMed Web of Science ®Google Scholar
• Li J, Hirose N, Kawamura M, Arai Y. Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis 1999;143:315–26
   PubMedGoogle Scholar
• Kohno M, Ohmori K, Nozaki S, Mizushige K, et al. Effects of valsartan on angiotensin II-induced migration of human coronary artery smooth muscle cells. Hypertens Res 2000;23:677–81
   PubMed Web of Science ®Google Scholar
• Tschudi MR, Criscione L, Novosel D, Pfeiffer K, et al. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries ofspontaneously hypertensive rats. Circulation 1994;89:2212–8
   PubMed Web of Science ®Google Scholar
• Gervais M, Richer C, Fornes P, De Gasparo M, et al. Valsartan and coronary haemodynamics in early post-myocardial infarction in rats. Fundam Clin Pharmacol 1999;13:635–45
   PubMedGoogle Scholar
• Allen TJ, Cao Z, Youssef S, Hulthen UL, et al. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997;46:1612–8
   Google Scholar
• Davis BJ, Cao Z, de Gasparo M, Kawachi H, et al. Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. J Hypertens 2003;21:209–16
   PubMed Web of Science ®Google Scholar
• Mann JF. Valsartan and the kidney: present and future. J Cardiovasc Pharmacol 1999;33 (Suppl):S37–40; S41–3
   Google Scholar
• Yu XQ, Wu LL, Huang XR, Yang N, et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int 2000;58:1469–80
   PubMedGoogle Scholar
• Cao Z, Bonnet F, Candido R, Nesteroff SP, et al. Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury.JAm Soc Nephrol 2002;13:1773–87
   Google Scholar
• Remuzzi A, Gagliardini E, Donadoni C, Fassi A, et al. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002;62:885–94
   PubMed Web of Science ®Google Scholar
• Hilgers KF, Hartner A, Porst M, Mai M, et al. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury. Kidney Int 2000;58:2408–19
   PubMed Web of Science ®Google Scholar
• Hilgers KF, Hartner A, Porst M, Veelken R, et al. Angiotensin II type 1 receptor blockade prevents lethal malignant hypertension: relation to kidney inflammation. Circulation 2001;104:1436–40
   PubMedGoogle Scholar
• Mervaala EM, Cheng ZJ, Tikkanen I, Lapatto R, et al. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 2001;37:414–8
   PubMed Web of Science ®Google Scholar
• de las Heras N, Aragoncillo P, Maeso R, Vazquez-Perez S, et al. AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999;34:969–75
   PubMedGoogle Scholar
• de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P, et al. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 2000;1:151–8
   PubMedGoogle Scholar
• Klingbeil AU, John S, Schneider MP, Jacobi J, et al. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003;16:123–8
   PubMed Web of Science ®Google Scholar
• Tzemos N, lim PO, McDonald TM. Valsartan improved endothelial function in patients with essential hypertension. Am J Hyperten 2001; 14:66–7A
   PubMedGoogle Scholar
• Dandona P, Kumar V, Aljada A, Ghanim H, et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action. J Clin Endocrinol Metab 2003;88:4496–501
   PubMed Web of Science ®Google Scholar
• Lottermoser K, Ulrich-Merzenich G, Vetter H, Dusing R. Effects of angiotensin II on inflammation mediators in healthy subjects. Dtsch Med Wochenschr 2003;128:2470–5
   Google Scholar
• Lopez B, Salom MG, Arregui B, Valero F, et al. Role of superoxide in modulating the renal effects of angiotensin II. Hypertension 2003;42:1150–6
   PubMed Web of Science ®Google Scholar
• Seeger H, Mueck AO, Lippert TH. Effects of valsartan and 17 beta-estradiol on the oxidation of low-density lipoprotein in vitro. Coron Artery Dis 2000;11:347–9
   PubMedGoogle Scholar
• Hussein O, Shneider J, Rosenblat M, Aviram M. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol 2002;40:28–34
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Poletti L, Marasi G, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001;14:27–31
   Google Scholar
• Fogari R, Preti P, Zoppi A, Corradi L, et al. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens 2004;17:77–81
   PubMedGoogle Scholar
• Chan P, Wong KL, Liu IM, Tzeng TF, et al. Antihyperglycemic action of angiotensin II receptor antagonist, valsartan, in streptozotocin-induced diabetic rats. J Hypertens 2003;21:761–9
   PubMedGoogle Scholar
• Chow L, De Gasparo M, Levens N. Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors. Eur J Pharmacol 1995;282:77–86
   PubMed Web of Science ®Google Scholar
• Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, et al. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 2001;37:433–9
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Abletshauser C. Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 2001; 29:270–9
   PubMed Web of Science ®Google Scholar
• Luzio SD, Dunseath G, Owens DR. Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes. Horm Metab Res 2002;34:271–4
   PubMedGoogle Scholar
• Top C, Cingozbay BY, Terekeci H, Kucukardali Y, et al. The effects of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res 2002;30:15–20
   PubMed Web of Science ®Google Scholar
• The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996;39:587–93
   PubMed Web of Science ®Google Scholar
• Devereux RB, Dahlof B, Kjeldsen SE, Julius S, et al. and the LIFE Study Group. Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med 2003;139:169–77
   Google Scholar
• Scheidegger KJ, Butler S, Witztum JL. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem 1997;272:21609–15
   PubMedGoogle Scholar
• Webb RL, Barclay BW, Navarrete AE, Wosu NJ, et al. Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1998;20:775–93
   PubMed Web of Science ®Google Scholar
• Oparil S, Dyke S, Harris F, Kief J, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996;18:797–810
   PubMed Web of Science ®Google Scholar
• Corea L, Cardoni O, Fogari R, Innocenti P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60:341–6
   PubMed Web of Science ®Google Scholar
• Holwerda NJ, Fogari R, Angeli P, Porcellati C, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996;14:1147–51
   PubMed Web of Science ®Google Scholar
• Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998;7:176–83
   PubMedGoogle Scholar
• Sagie A, Larson M.G, Levy D. The natural history of borderline isolated systolic hypertension. N Engl J Med 1993;329:1912–7
   Google Scholar
• SHEP investigators. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hyper-tension in the Elderly Program (SHEP). JAMA 1991;265:3255–64
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Dahlof B, Devereux RB, Julius S, et al. and the LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491–8
   PubMed Web of Science ®Google Scholar
• Neutel JM, Bedigian MP. Efficacy of valsartan in patients aged 4 or = 65 years with systolic hypertension. Clin Ther 2000;22:961–9
   PubMed Web of Science ®Google Scholar
• Malacco E, Vari N, Capuano V, Spagnuolo V, et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Clin Ther 2003;25:2765–80
   PubMed Web of Science ®Google Scholar
• Vergoulas G, Miserlis GR, Gakis D, Atmatzidis E, et al. The use of valsartan in hypertensive renal transplant recipients. Hippokratia 2001;5:61–8
   Google Scholar
• Gottdiener JS, Reda DJ, Massie BM, Materson BJ, et al. for the VA Cooperative Study Group on Antihypertensive Agents. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension. Comparison of six antihypertensive agents. Circulation 1997;95:2007–14
   Google Scholar
• Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996;275:1507–13
   Google Scholar
• Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. Meta-analysis of 109 treatment studies. Am J Hypertens 1992;5:95–110
   PubMed Web of Science ®Google Scholar
• Thurmann PA, Kenedi P, Schmidt A, Harder S, et al. Influence of the Angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hyper-tension. Circulation 1998;98:2037–42
   PubMed Web of Science ®Google Scholar
• Mutlu H, Ozhan H, Okcun B, Okuyan E, et al. The efficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy. Blood Press 2002;11:53–5
   PubMed Web of Science ®Google Scholar
• Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003;139:901–6
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Berl T, et al. and the Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Keane SF, et al. Effects of Losartan on renal and cardiovascular outcome in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group, N Engl J Med 1993;329:1456–62
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672–8
   PubMed Web of Science ®Google Scholar
• Pahor M, Psaty BM, Furberg CD. Treatment of hyper-tensive patients with diabetes. Lancet 1998;351:689–90
   PubMed Web of Science ®Google Scholar
• Muirhead N, Feagan BF, Mahon J, Lewanczuk RZ, et al. The effects of valsartan and captopril on reducing microalbuminuria in patients with type 2 mellitus: a placebo-controlled trial. SO Curr Ther Res - Clin Exper 1999;60:650–60
   Web of Science ®Google Scholar
• Suzuki K, Souda S, Ikarashi T, Kaneko S, et al. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract 2002;57:179–83
   PubMed Web of Science ®Google Scholar
• Shvetsov MIu, Medvedeva TIu, Kozlovskaia NL, Miroshnichenko NG, et al. Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis. Ter Arkh 2001;73:55–6
   Google Scholar
• Plum J, Bunten B, Nemeth R, Grabensee B. Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension. Nephrol Dial Transplant 1999;14 (Suppl):25–7
   Google Scholar
• Horino T, Ito H, Tanimoto N, Yoshida T, et al. Successful treatment of combination therapy using an Angiotensin-converting enzyme inhibitor and an Angiotensin II receptor blocker in a patient with IgA nephropathy]. Nippon Jinzo Gakkai Shi 2003;45:104–8
   PubMedGoogle Scholar
• SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991;325:293–302
   PubMed Web of Science ®Google Scholar
• Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, et al. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol 1998;65:239–46
   PubMed Web of Science ®Google Scholar
• De Tommasi E, Iacoviello M, Romito R, Ceconi C, et al. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J 2003;146:E17
   Google Scholar
• Jorde UP, Ennezat PV, Lisker J, Suryadevara V, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844–6
   PubMed Web of Science ®Google Scholar
• Willenheimer R, Helmers C, Pantev E, Rydberg E, et al. and the Heart Failure Valsartan Exercise Capacity Evaluation Study Group. Safety and efficacy of valsartan versus enalapril in heart failure patients. Int J Cardiol 2002;85:261–70
   Google Scholar
• Kasama S, Toyama T, Kumakura H, Takayama Y, et al. Addition of valsartan to an Angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med 2003;44:884–90
   PubMed Web of Science ®Google Scholar
• Cuocolo A, Storto G, Izzo R, Iovino GL, et al. Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril. J Hypertens 1999;17:1759–66
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75
   Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K, Granger CB, et al. and the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–81
   Google Scholar
• Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, et al. and the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–906
   Google Scholar
• Wilensky RL. Angiotensin-receptor blockers: revival of the systemic prevention of restenosis? Cardiovasc Drugs Ther 2003;17:63–73
   PubMed Web of Science ®Google Scholar
• Jandeleit-Dahm K, Burrell LM, Johnston CI, Koch KM. Elevated vascular angiotensin converting enzyme mediates increased neointima formation after balloon injury in spontaneously hypertensive rats. J Hypertens 1997;15:643–50
   PubMedGoogle Scholar
• Feng TC, Ying WY, Hua RJ, Ji YY, et al. Effect of valsartan and captopril in rabbit carotid injury. Possible involvement of bradykinin in the antiproliferative action of the renin-angiotensin blockade. J Renin Angiotensin Aldosterone Syst 2001;2:19–24
   PubMed Web of Science ®Google Scholar
• Peters S, Gotting B, Trummel M, Rust H, et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardiol 2001;13:93–7
   PubMed Web of Science ®Google Scholar
• Kaiser HJ, Graf T, Krejci G, Mathis GA, et al. A new Angiotensin-II- receptor blocker, CGP 48933: local tolerance and effect on intraocular pressure. A pilot study. Eur J Ophthalmol 1997;7:35–9
   PubMedGoogle Scholar
• Biswas PN, Wilton LV, Shakir SW. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England. J Hum Hypertens 2002;16:795–803
   PubMed Web of Science ®Google Scholar
• Pool JL, Glazer R, ChiAng YT, Gatlin M. Dose-response efficacy of valsartan, a new Angiotensin II receptor blocker. J Hum Hypertens 1999;13:275–81
   PubMed Web of Science ®Google Scholar
• Thomas MC. Diuretics, ACE inhibitors and NSAIDs - the triple whammy. Med J Aust 2000;172:184–5
   PubMed Web of Science ®Google Scholar
• Bakris GL, Siomos M, Richardson D, Janssen I, et al. ACE inhibition or Angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000;58:2084–92
   PubMed Web of Science ®Google Scholar
• Benz J, Oshrain C, Henry D, Avery C, et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing theincidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997;37:101–7
   Google Scholar
• Martinez Alonso JC, Dominguez Ortega FJ, Mendez Alcalde J, Fuentes Gonzalo MJ. Angioedema due to valsartan. Allergy 2003;58:367
   Google Scholar
• Frye CB, Pettigrew TJ. Angioedema and photosensitive rash induced by valsartan. Pharmacotherapy 1998;18:866–8
   PubMed Web of Science ®Google Scholar
• Irons BK, Kumar A. Valsartan-induced Angioedema. Ann Pharmacother 2003;37:1024–7
   PubMed Web of Science ®Google Scholar
• Flais MJ. Literature reports of angiotensin receptor antagonist-induced angioedema in patients with a history of angiotensin-converting enzyme inhibitor-induced angioedema. Arch Intern Med 2003;163:1488
   Google Scholar
• Momken I, Kahapip J, Bahi L, Badoual T, et al. Does angiotensin-converting enzyme inhibition improve the energetic status of cardiac and skeletal muscles in heart failure induced by aortic stenosis in rats? J Mol Cell Cardiol 2003;35:399–407
   PubMed Web of Science ®Google Scholar
• Ahmed A, Kiefe CI, Allman RM, Sims RV, et al. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002;50:1659–66
   PubMed Web of Science ®Google Scholar
• Johansen TL, Kjaer A. Reversible renal impairment induced by treatment with the Angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrol 2001;2:1
   Google Scholar
• Karanikas G, Becherer A, Wiesner K, Dudczak R, et al. ACE inhibition is superior to Angiotensin receptor blockade for renography in renal artery stenosis. Eur J Nucl Med Mol Imaging 2002;29:312–8
   PubMed Web of Science ®Google Scholar
• Briggs GG, Nageotte MP. Fatal fetal outcome with the combined use of valsartan and atenolol. Ann Pharmac-other 2001;35:859–61
   PubMed Web of Science ®Google Scholar
• Martinovic J, Benachi A, Laurent N, Daikha-Dahmane F, et al. Fetal toxic effects and Angiotensin-II-receptor antagonists. Lancet 2001;358:241–2
   PubMed Web of Science ®Google Scholar
• Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003;14:992–9
   PubMed Web of Science ®Google Scholar
• Krum H, Nolly H, Workman D, He W, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002;40:117–23
   PubMed Web of Science ®Google Scholar
• Miller AB, Srivastava P. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure. Cardiol Clin 200;19:195–202
   Google Scholar
• Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75
   PubMed Web of Science ®Google Scholar
• De Leeuw PW. Nonsteroidal anti-inflammatory drugs and hypertension. The risk in perspective. Drugs 1996;51:179–87
   Google Scholar
• Fricker AF, Nussberger J, Meilenbrock S, Brunner HR, et al. Effect of indomethacin on the renal response to angiotensin II receptor blockade in healthy subjects. Kidney Int 1998;54:2089–97
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Carretta R, Veglio F, et al. and the Italian Collaborative Study Group. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. J Hypertens 2002;20:1007–14
   Google Scholar
• Boyd IW, Mathew TH, Thomas MC. COX-2 inhibitors and renal failure: the triple whammy revisited. Med J Aust 2000;173:274
   Google Scholar
• Oi S, Haneda T, Osaki J. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 1999;376:139–48
   PubMed Web of Science ®Google Scholar
• Horiuchi M, Cui TX, Li Z, Li JM, et al. Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003;107:106–12
   PubMed Web of Science ®Google Scholar